Endoscopic Surgery Tools in Massachusetts

Myriad Fiber Imaging Technologies is an ISO 13485-certified medical device manufacturer specializing in ultra-precision micro-endoscopy and visualization systems. Founded in 1995, the company designs and manufactures sub-1mm diameter fiberscopes, videoscopes, and CMOS imaging endoscopes ranging from 0.37mm to 5mm in diameter. MFI offers comprehensive OEM contract manufacturing, including electronic assembly, CMOS imaging systems, optical design, image processing, CNC machining, and micro-optics assembly. The company operates an 18,000 sq ft ISO-certified facility with 30+ years of technical expertise, serving primarily the medical sector (80% of business) alongside government, aerospace, and industrial applications. MFI is a U.S. distributor of Fujikura fiber optics and OmniVision CMOS sensors, providing both high-volume production and low-volume prototyping capabilities.

Precision Optics Corp. is a vertically integrated optical imaging systems and components manufacturer specializing in micro-precision optics for minimally invasive medical procedures. The company designs, prototypes, and manufactures CMOS endoscopic cameras, micro-optics assemblies (including custom lenses and prisms), fiber bundle scopes, and rod lens systems for endoscopy, 3D visualization, and robotic surgery applications. Their products serve challenging anatomical environments requiring miniaturization down to 0.37 mm lenses and 0.10 mm prisms, addressing applications in gastroenterology, laparoscopy, arthroscopy, and other minimally invasive surgical specialties. Precision Optics offers the Unity™ Imaging Platform, a modular, proven system supporting development from prototyping through production. The company combines opto-mechanical design, optical assembly expertise, and interdisciplinary engineering capabilities to deliver customized solutions meeting specific clinical and manufacturing standards. Beyond medical devices, Precision Optics serves defense and aerospace sectors with micro-optical components. The firm is recognized as a domestic optics manufacturing partner with rapid response capabilities for complex imaging and illumination requirements in confined surgical spaces.

Morphic Medical is a Boston-based MedTech company founded in 2003 specializing in innovative, minimally invasive device therapies for type 2 diabetes and obesity. The company's flagship product, RESET® therapy, is an endoscopically delivered device designed to address the underlying metabolic causes of type 2 diabetes and weight gain. RESET targets patients underserved by traditional pharmaceuticals and injections who are unsuitable for bariatric surgery, aiming to reduce HbA1c levels and body weight while improving glycemic control and cardiovascular risk profile. Currently investigational in the United States, RESET is undergoing clinical validation through the STEP-1 trial. Morphic Medical bridges the therapeutic gap between medical management and surgical intervention, offering a non-surgical alternative that leverages endoscopic delivery mechanisms to achieve durable metabolic benefits.

Olympus Corporation is a global medical technology company specializing in endoscopic imaging, endotherapy devices, and therapeutic energy devices for early detection, diagnosis, and minimally invasive treatment. The company manufactures medical endoscopes and related endotherapy systems serving gastroenterology, pulmonology, bronchial interventions, and surgical specialties. Olympus operates through its CONTINUUM professional education platform and maintains a broad portfolio of minimally invasive diagnostic and therapeutic solutions. The company emphasizes early screening and detection capabilities, particularly in colorectal and bronchial pathologies, supported by advanced imaging platforms and energy-based therapeutic devices. Olympus has divested its Life Science Solutions and Industrial Solutions divisions (now under Evident) and camera/audio/binoculars business (now under OM Digital Solutions), focusing its portfolio on medical device manufacturing and healthcare solutions. The company is a multinational medtech enterprise with strong commitments to clinical innovation, regulatory compliance, and global market distribution.

Emmy Medical manufactures CystoSure®, a patented diagnostic device that combines urinary catheter and cystoscope functionality for safe, efficient visualization of the female bladder and ureteral openings. The device features a novel pancake balloon and low-profile catheter tip enabling standardized placement and optimal trigonal ridge positioning for comprehensive bladder diagnostics. CystoSure® is designed for use in both operating room and office settings, reducing procedural time, instrument exchange, and infection risk while enabling single-visit diagnostic cystoscopy. Compatible with standard 2.9 mm hysteroscopes, the system streamlines urological evaluation without requiring complex cystoscopy trays.

Body Vision Medical is a commercial-stage medical device company specializing in AI-powered imaging solutions for lung cancer detection and intervention. The company's flagship product, the LungVision® system, transforms standard 2D C-arm X-ray images into advanced 3D intraoperative imaging for enhanced navigation during endobronchial biopsies. Utilizing proprietary AI Tomo® technology, LungVision corrects for CT-to-body divergence and enables tool-in-lesion confirmation, improving diagnostic yield from traditional 55-75% to approximately 90-95% for small pulmonary lesions. The system delivers superior economics with lower total cost of ownership than robotic alternatives, reduced radiation exposure (1/5 of 3D C-arms), and accessibility worldwide. Founded in 2014 by engineers experienced in electromagnetic navigation bronchoscopy, Body Vision empowers pulmonologists and thoracic surgeons with real-time, high-precision navigation for biopsy and localized therapy delivery. Recognized as a Top Medtech Startup in 2023.

D&R Products is a contract manufacturer of medical devices headquartered in Hudson, Massachusetts, with over 80 years of continuous American manufacturing and 38 years of specialized focus on medical device outsourcing. The company operates a 43,000 square-foot facility providing turnkey manufacturing from bar stock to finished device. D&R holds ISO 13485-2016 certification and maintains in-house control over key manufacturing processes including CNC machining (Swiss turning, wire EDM), secondary operations (deburring, electropolishing, passivation, laser marking), precision welding (laser, palm arc, resistance), and clean room assembly (ISO Class 7 and 8). The company specializes in exotic materials including nitinol, titanium, stainless steel, and engineered polymers (PEAK, Radel). Product specialties include minimally invasive surgical devices, arthroscopic shaver blades and burrs, RF electrodes, soft tissue refixation implants, specialty needles, cannulas, and trocars. D&R maintains direct executive and engineering engagement for each customer project, offering design-for-manufacturability consultation and custom process development. The company reports being a sole-source supplier on over 75% of products and counts 6 of the 7 largest medical device companies among its customer base. Manufacturing capabilities span small lots through millions of units with documented traceability and quality system control.

Paradigm Biodevices is a medical device company specializing in minimally invasive surgical solutions for orthopedic fusion procedures, particularly autogenous bone grafting. The company has established clinical expertise through its flagship QuickDraw MIS Bone Harvester, a percutaneous bone harvesting system for iliac crest bone grafting that has been used in over 40,000 procedures at elite orthopedic hospitals across the United States and global markets. Paradigm has recently launched VisiCORE™, a proprietary next-generation bone harvester designed for extremity fusions, developed in collaboration with foot and ankle surgeon innovators. The company focuses on addressing surgical technique challenges in fusion procedures, enabling surgeons to harvest autograft bone with improved visibility, precision, and efficiency while maintaining the gold-standard composition of autograft scaffolds, cells, and signaling factors. Products are used in spine fusion and extremity fusion applications, serving orthopedic surgical centers, teaching hospitals, and specialized orthopedic programs. Paradigm holds ISO 13485 certification, demonstrating compliance with medical device quality management standards. The company participates actively in major orthopedic conferences including ACFAS, AOFAS, and NASS annual meetings, and provides hands-on surgical instruction and demonstration programs for surgeons.

Medovate Limited is a UK-based medical device development and commercialization company specializing in bringing novel clinical innovations to market through structured partnerships with NHS clinicians and healthcare providers. The company operates across the full medical device development pipeline—from initial concept evaluation and clinical development through regulatory approval and global market launch. Medovate's current product portfolio includes Safira® (regional anesthesia injection safety system with automatic pressure limiting to reduce nerve injury risk), Glucosave® (critical care blood sampling safety device to prevent inappropriate insulin administration), Humidicare® (heat and moisture exchanger with visual alerts for mechanical ventilation circuits), LUMEVAC™ (endoscopic surgical device for management of life-threatening gastrointestinal tract infections), and CamPROBE (transperineal prostate biopsy facilitation device). The company leverages deep relationships with NHS institutions to validate medical needs, conduct clinical trials, and accelerate adoption of approved technologies. Medovate focuses on patient safety innovations and clinician-centered design, with demonstrated capability in securing regulatory clearance and driving market entry across multiple therapeutic domains including anesthesia, critical care, endoscopic surgery, and urology. The firm's model emphasizes unmet clinical needs resolution and cost-effective solutions for healthcare systems globally.

Origami Surgical Inc. develops StitchKit, a specialized device designed to address a critical patient safety and operational efficiency challenge in robotic minimally invasive surgery: the management of exposed needle transfer during surgical procedures. The company's core focus is on preventing retained surgical sharps—a never event associated with significant morbidity, extended operative time, and substantial additional medical costs ($70,000–$200,000 per incident). StitchKit optimizes both safety and surgical efficiency by reducing needle exchanges during procedures, eliminating the risk of lost needles, and enhancing surgeon autonomy. Clinical evidence from published studies in 422 patients demonstrates safety and efficacy, with no reported hernias, infections, or adverse events. The device also enables reduction of operative ports and decreases reliance on skilled bedside assistants. Origami Surgical targets robotic surgery programs and OR teams performing minimally invasive procedures where needle management is a recurring operational and safety concern. The company positions itself in the growing robotic surgery market (15.7% CAGR over 10 years) where 91% of surgeons report one to five lost sharps incidents annually, with over 80% of needle loss occurring during trocar retrieval.

Opus KSD designs, manufactures, and distributes SubQ It!, an FDA-cleared, ISO 13485-registered bioabsorbable dermal fastener system for surgical wound closure. SubQ It! is a subcuticular stapler that combines the speed of metal staples with the cosmetic results of sutures, without requiring removal or piercing the skin. The device delivers 7X faster closure than traditional sutures and is specifically designed for closing small incisions, laparoscopic trocar sites, and longer surgical wounds (up to 25cm). Available in two product lines—SU-10 and SU-25—it eliminates patient discomfort associated with metal staple removal and reduces operative time. The device is ideal for minimally invasive surgery (MIS) and general surgical applications.

Integra LifeSciences Corporation is a global medical technology company specializing in surgical, neurologic, and regenerative care products. The company manufactures and distributes a comprehensive portfolio spanning neurosurgery (dural repair, cranial reconstruction, hydrocephalus management, CSF drainage systems, multimodal neuro-critical care monitoring), wound reconstruction and care (engineered collagen, fetal bovine dermis, urinary bladder matrix, amniotic tissue, Manuka honey dressings, total contact casting), surgical reconstruction (nerve and tendon repair, hernia repair, plastic and reconstructive surgery), surgical instrumentation and lighting (including brands Jarit®, MicroFrance®, Omni-Tract®, Ruggles®-Redmond™, Padgett®, and Miltex®), and ear, nose and throat devices (airway dilation systems, balloon sinuplasty, nasal dilation, Eustachian tube dilation, navigation systems). The company serves hospitals, surgery centers, and tissue banks globally. Integra maintains extensive international operations with customer service, repair, and medical inquiry support across North America, Europe, Asia-Pacific, and other regions. The company provides clinical documentation, IFUs (Instructions for Use), and regulatory support resources on its products portal.

Summa Therapeutics is a commercial-stage medical device company specializing in advanced catheter technologies for peripheral vascular interventions. The company develops multifunctional catheters designed to improve the efficiency, safety, and economics of below-the-knee (BTK) revascularization procedures for patients with peripheral arterial disease (PAD). Summa's flagship product, Finesse BTK Multicath™, is an FDA-cleared trimodal catheter that combines crossing, diagnostic angiography, and angioplasty balloon functions in a single device. This integrated approach reduces the need for multiple catheter exchanges during complex peripheral interventions, thereby decreasing procedure time, radiation exposure, and contrast agent use—particularly important for at-risk patients with diabetes or chronic kidney disease. The Finesse product line, including the newly cleared Gen 2 injectable angioplasty balloon variant, addresses a critical clinical need in limb-salvage interventions, streamlining workflows and improving patient outcomes while reducing operator strain.

Agile Devices is a Boston-based medical device development company specializing in innovative steerable and deflectable catheter technologies for interventional procedures. The company's flagship product, the Angler® microcatheter, features active tip control technology that enables clinicians to adjust the catheter tip angle in situ during procedures. This proprietary design reduces the need for device exchanges, thereby minimizing procedure time, radiation exposure, cost, and procedural risk. The technology is particularly valuable in interventional radiology, cardiology, and neuroradiology applications where vessel navigation challenges—such as tortuosity, acute branch angles, and atherosclerotic disease—are common. FDA-cleared for peripheral and coronary vascular use, Agile Devices' steerable microcatheters address critical clinical gaps in catheter navigation, improving outcomes in complex vascular interventions including embolization procedures and coronary angiography.

Interscope, Inc. is a medical device manufacturer specializing in minimally invasive interventional endoscopic solutions for gastroenterology and pulmonology. The company's flagship product is the EndoRotor® System, an innovative powered endoscopic device designed for tissue resection, debridement, and removal in the gastrointestinal tract. The EndoRotor® addresses critical clinical needs including endoscopic necrosectomy, management of walled-off pancreatic necrosis (WOPN), incomplete lesion resection, post-EMR scarred lesions, Barrett's esophagus treatment, and difficult-to-reach polyp removal. The device functions as a 3-in-1 tool enabling simultaneous dissection, resection, and tissue collection. With FDA 510(k) clearance for Endoscopic Powered Resection (EPR) and FDA De Novo approval for Powered Endoscopic Debridement (PED), the EndoRotor® is distributed directly in the U.S. market. Interscope collaborates with leading academic medical centers including Duke University Medical Center, Mayo Clinic, and the Arizona Center for Digestive Health to validate clinical efficacy and procedural outcomes.